glp-1 and parkinson's disease Some epidemiologic studies have suggested that the risk of is increased among persons with type 2 #Diabetes, with the risk potentially attenuated in those taking glucagon-like peptide-1 (GLP-1) receptor agonists GLP-1 Drugs and Parkinson's Disease:

A Cleveland Clinic analysis of nearly 8,000 patients found that discontinuing semaglutide and tirzepatide did not lead to significant immediate weight regain in clinical practice

Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the global collaborative network

There are also FDA-approved generic liraglutide products for Victoza (for Type 2 diabetes and cardiovascular risk reduction) and Saxenda (for weight management)

This inside-outside approach gives the best results

While oral and injectable routes dominate consumer markets, intranasal delivery is increasingly favored in experimental pharmacology for bypassing hepatic first-pass metabolism and ensuring more rapid compound absorption into systemic circulation

I have to say that I do take issue with the thought of a cure for it, Washington said